Who we are
NAICONS is a biotechnology company that has developed a proprietary Platform called micro4all, the first Molecule search engine that is going to redefine the Drug Discovery Process.
Who we are
What differentiates us from our competitors is our people and our purpose. We combine the rigor and thoroughness of the academic world with the efficiency and focus of industry. When planning a project, we maintain a very high quality of experimental design and execution processes, yet follow constraints about budget, timelines, and confidentiality. Read on to learn more about who we are and why we're so different from our competitors.
Our vision
Become a global leader in providing game-changing Discovery solutions to our target markets (drugs, cosmetics, food and beverage) by creating a breakthrough Platform that puts together outstanding assets and knowhow in natural products with state-of-the-art Data Science.
Our mission
Naicons is a game-changing platform that allows effective discovery of promising natural products for a variety of applications.
Our target is the entire research community, both industry and academia, interested in finding new drug leads for multiple applications, new additives in cosmetics, foods and beverages, and in using natural products to probe biological processes.
We have developed a Proprietary Platform that merges diversified biological resources and knowhow in natural products with big data and artificial intelligence to provide a rapid identification of the Molecules of interest.
Our Platform, named Micro4all, is going to provide the first Search-and-Order Molecules Engine available through an online subscription.
The combination of proprietary Assets and Workflow, along with Knowhow and Accessibility, are unmatched by anyone at a Global Level today.
Efficiency of the Discovery process and Time to Market are our key Differentiators.
Our history
NAICONS Srl, founded in late 2013 by twelve individuals previously involved in similar initiatives, was established with the objective of commercializing a series of assets related to microorganisms and the many molecules they produce.
The incorporation of NAICONS Srl was de facto a repositioning to a for-profit organization of New Anti-Infectives Consortium Scrl, a not-for-profit organization with a complex shareholder structure set up in late 2006 with the objective of acquiring assets (among others, the strain collection and a few patents) that were present in the Biosearch Italia/Vicuron drug discovery center located in Gerenzano, Italy, just NW of Milan.
Many of NAICONS Srl founders were actually founders, shareholders and/or key figures of Biosearch Italia, a company set up in 1996 as a spinoff of the Lepetit Research Center - at that time owned by Hoechst Marion Roussel, then a big pharma company, now part of Sanofi. Biosearch Italia was the first Italian biotech company to be publicly listed in the Italian stock exchange in 2000 and, after its merger with a similarly-sized American company in 2003, had a dual listing in Nasdaq and in Nuovo Mercato as Vicuron. In 2005, Pfizer acquired Vicuron for its late-stage antibiotics for 1.9 B$, and the assets mentioned before had become available for bidders when Pfizer decided to close the research facilities in Gerenzano. Those acquired assets, plus others discovered and developed since 2006, represent the key elements of NAICONS technology platform.
Today Naicons is developing micro4all, the first Search-and-Order Molecules Engine available through an online subscription that is going to redefine the whole Drug Discovery Process.
Our team
NAICONS’ team consists of talented scientists that over the last three decades have worked together to define and realize the actual NAICONS’ business model. A group of young and talented scientists joined since 2013 to help and support NAICONS to develop micro4all concept and prototype. Today the team is growing and embracing Data Analysis and IA competence to set the ground of micro4all development and go to market.
